| No. |
Drug (Description in trials) |
DrugBank |
KEGG DRUG * |
KEGG GENES * [Number of genes] |
KEGG PATHWAY [Number of pathways] |
Disease ID * [Number of diseases] |
| 1 |
1-20190 |
- |
- |
- |
- |
[1] 93 |
| 2 |
11c-csar |
- |
- |
- |
- |
[2] 93, 94 |
| 3 |
13-15mg/kg/d ursodeoxycholic |
- |
- |
- |
- |
[1] 93 |
| 4 |
18-22mg/kg/d ursodeoxycholic |
- |
- |
- |
- |
[1] 93 |
| 5 |
3 mg [14c]-a4250 capsule |
- |
- |
- |
- |
[2] 93, 297 |
| 6 |
6 alpha-ethylchenodeoxycholic acid (6-edca), oca, int-747 |
- |
- |
- |
- |
[1] 93 |
| 7 |
6-ethylchenodeoxycholic acid |
Obeticholic acid |
D09360 |
[1] NR1H4 |
[1] Bile secretion |
[1] 93 |
| 8 |
6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o |
Obeticholic acid |
D09360 |
[1] NR1H4 |
[1] Bile secretion |
[1] 93 |
| 9 |
6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o, obeticholic acid (oca) |
Obeticholic acid |
D09360 |
[1] NR1H4 |
[1] Bile secretion |
[1] 93 |
| 10 |
6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o |
Obeticholic acid |
D09360 |
[1] NR1H4 |
[1] Bile secretion |
[1] 93 |
| 11 |
6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o, obeticholic acid (oca) |
Obeticholic acid |
D09360 |
[1] NR1H4 |
[1] Bile secretion |
[1] 93 |
| 12 |
6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o |
Obeticholic acid |
D09360 |
[1] NR1H4 |
[1] Bile secretion |
[1] 93 |
| 13 |
6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o , obeticholic acid (oca) |
Obeticholic acid |
D09360 |
[1] NR1H4 |
[1] Bile secretion |
[1] 93 |
| 14 |
6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o |
Obeticholic acid |
D09360 |
[1] NR1H4 |
[1] Bile secretion |
[1] 93 |
| 15 |
6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o , obeticholic acid (oca) |
Obeticholic acid |
D09360 |
[1] NR1H4 |
[1] Bile secretion |
[1] 93 |
| 16 |
A11ha02 |
- |
- |
- |
- |
[1] 93 |
| 17 |
A4250 |
- |
- |
- |
- |
[2] 93, 297 |
| 18 |
Abatacept |
Abatacept |
D03203 |
[2] CD80, CD86 |
[12] Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
[24] 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 96, 97, 107, 164, 222, 271, 284, 285, 300 |
| 19 |
Apd334 |
- |
- |
- |
- |
[4] 93, 96, 97, 269 |
| 20 |
Atorvastatin |
Atorvastatin |
D00258, D00887, D07474 |
[1] HMGCR |
[4] AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
[17] 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 160, 222, 225, 265, 271, 299 |
| 21 |
Baricitinib |
Baricitinib |
D10308 |
[2] JAK1, JAK2 |
[32] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
| 22 |
Bcd-085 |
- |
- |
- |
- |
[2] 93, 271 |
| 23 |
Bezafibrat |
- |
- |
- |
- |
[1] 93 |
| 24 |
Bezafibrat genericon retard 400 mg |
- |
- |
- |
- |
[1] 93 |
| 25 |
Bezafibrate |
Bezafibrate |
D01366 |
[1] PPARA |
[7] Adipocytokine signaling pathway, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease (NAFLD), PPAR signaling pathway, cAMP signaling pathway |
[5] 20, 93, 94, 160, 316 |
| 26 |
Bezalip |
- |
- |
- |
- |
[2] 93, 94 |
| 27 |
Budenofalk 3mg |
- |
- |
- |
- |
[2] 93, 97 |
| 28 |
Budesonide |
Budesonide |
D00246 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[9] 66, 93, 94, 95, 96, 97, 98, 228, 299 |
| 29 |
Calcium |
Calcium |
- |
- |
- |
[24] 6, 13, 19, 46, 49, 51, 65, 68, 75, 79, 84, 93, 94, 95, 96, 97, 214, 215, 222, 224, 235, 265, 298, 299 |
| 30 |
Cilofexor |
Cilofexor |
- |
- |
- |
[2] 93, 94 |
| 31 |
Colchicine |
Colchicine |
D00570 |
[9] TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 |
[3] Gap junction, Pathogenic Escherichia coli infection, Phagosome |
[5] 2, 42, 56, 93, 266 |
| 32 |
Combination antiviral therapy |
- |
- |
- |
- |
[1] 93 |
| 33 |
Cr845 1.0 mg |
- |
- |
- |
- |
[1] 93 |
| 34 |
Crc (a3384) |
- |
- |
- |
- |
[2] 93, 297 |
| 35 |
Cyclophosphamide |
Cyclophosphamide |
D00287, D07760 |
- |
- |
[43] 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 61, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 222, 224, 265, 274, 283, 284, 285, 288, 326, 331 |
| 36 |
Denosumab |
Denosumab |
D03684 |
[1] TNFSF11 |
[7] Breast cancer, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis |
[7] 46, 50, 93, 95, 96, 274, 299 |
| 37 |
E6011 |
- |
- |
- |
- |
[3] 46, 93, 96 |
| 38 |
Edp-305 |
- |
- |
- |
- |
[1] 93 |
| 39 |
Edp-305 dose 1 |
- |
- |
- |
- |
[1] 93 |
| 40 |
Edp-305 dose 2 |
- |
- |
- |
- |
[1] 93 |
| 41 |
Elafibranor |
Elafibranor |
D11208 |
[1] PPARA |
[7] Adipocytokine signaling pathway, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease (NAFLD), PPAR signaling pathway, cAMP signaling pathway |
[1] 93 |
| 42 |
Elafibranor 120 mg |
Elafibranor |
D11208 |
[1] PPARA |
[7] Adipocytokine signaling pathway, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease (NAFLD), PPAR signaling pathway, cAMP signaling pathway |
[1] 93 |
| 43 |
Elafibranor 80 mg |
Elafibranor |
D11208 |
[1] PPARA |
[7] Adipocytokine signaling pathway, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease (NAFLD), PPAR signaling pathway, cAMP signaling pathway |
[1] 93 |
| 44 |
Emtricitabine |
Emtricitabine |
D01199 |
- |
- |
[4] 25, 93, 265, 325 |
| 45 |
Emtricitabine (ftc)/tenofovir disoproxil (tdf) |
Tenofovir disoproxil |
D01982 |
- |
- |
[1] 93 |
| 46 |
Ezetimibe |
Ezetimibe |
D01966 |
[1] NPC1L1 |
[1] Fat digestion and absorption |
[4] 49, 79, 93, 260 |
| 47 |
Ezetrol |
Ezetimibe |
D01966 |
[1] NPC1L1 |
[1] Fat digestion and absorption |
[2] 93, 260 |
| 48 |
Fenofibrate |
Fenofibrate |
D00565 |
[1] PPARA |
[7] Adipocytokine signaling pathway, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease (NAFLD), PPAR signaling pathway, cAMP signaling pathway |
[5] 8, 79, 93, 94, 265 |
| 49 |
Fenofibrate (insoluble drug delivery-micro particle fenofibrate (idd-p) |
Fenofibrate |
D00565 |
[1] PPARA |
[7] Adipocytokine signaling pathway, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease (NAFLD), PPAR signaling pathway, cAMP signaling pathway |
[1] 93 |
| 50 |
Ffp104 |
- |
- |
- |
- |
[2] 93, 96 |
| 51 |
Fully human monoclonal antibody directed against cxcl10 |
- |
- |
- |
- |
[1] 93 |
| 52 |
Fuzhenghuayu |
- |
- |
- |
- |
[1] 93 |
| 53 |
Gft505 |
- |
- |
- |
- |
[1] 93 |
| 54 |
Gkt137831 |
- |
- |
- |
- |
[2] 85, 93 |
| 55 |
Gsk2330672 |
Gsk2330672 |
- |
- |
- |
[1] 93 |
| 56 |
High protein high fiber diet |
- |
- |
- |
- |
[2] 93, 95 |
| 57 |
Int-747 |
- |
- |
- |
- |
[1] 93 |
| 58 |
Int-747, oca |
- |
- |
- |
- |
[2] 93, 94 |
| 59 |
Liver biopsy |
- |
- |
- |
- |
[1] 93 |
| 60 |
Lum001 |
- |
- |
- |
- |
[3] 93, 94, 297 |
| 61 |
Mabthera® |
- |
- |
- |
- |
[6] 13, 35, 43, 44, 46, 93 |
| 62 |
Magnesium |
Magnesium |
- |
- |
- |
[15] 6, 11, 13, 46, 64, 93, 97, 166, 225, 235, 284, 291, 296, 297, 298 |
| 63 |
Mbx 8025 |
- |
- |
- |
- |
[1] 93 |
| 64 |
Mbx-8025 |
- |
- |
- |
- |
[2] 79, 93 |
| 65 |
Mbx-8025 10 mg capsule |
- |
- |
- |
- |
[1] 93 |
| 66 |
Mbx-8025 2 mg capsule |
- |
- |
- |
- |
[1] 93 |
| 67 |
Mbx-8025 5 mg capsule |
- |
- |
- |
- |
[1] 93 |
| 68 |
Mesenchymal stem cell |
- |
- |
- |
- |
[2] 2, 93 |
| 69 |
Methionine |
Methionine |
D00019, D04983 |
- |
- |
[6] 34, 75, 84, 93, 229, 300 |
| 70 |
Methotrexate |
Methotrexate |
D00142, D02115 |
[2] DHFR, DHFR2 |
[4] Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
[33] 11, 13, 19, 34, 35, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 162, 164, 172, 256, 271, 284, 285, 326, 331 |
| 71 |
Minodronic acid |
Minodronic acid |
- |
- |
- |
[4] 6, 46, 93, 95 |
| 72 |
Modafinil |
Modafinil |
D01832 |
- |
- |
[4] 6, 13, 49, 93 |
| 73 |
Moexipril |
Moexipril |
D00623, D08225 |
[1] ACE |
[4] Chagas disease (American trypanosomiasis), Hypertrophic cardiomyopathy (HCM), Renin secretion, Renin-angiotensin system |
[1] 93 |
| 74 |
Ngm282 |
- |
- |
- |
- |
[2] 93, 94 |
| 75 |
Ni-0801 |
- |
- |
- |
- |
[1] 93 |
| 76 |
Non-myeloablative hematopoietic stem cell transplantation |
- |
- |
- |
- |
[1] 93 |
| 77 |
Obeticholic acid |
Obeticholic acid |
D09360 |
[1] NR1H4 |
[1] Bile secretion |
[3] 93, 265, 296 |
| 78 |
Obeticholic acid (oca) |
Obeticholic acid |
D09360 |
[1] NR1H4 |
[1] Bile secretion |
[1] 93 |
| 79 |
Oca (int-747) |
- |
- |
- |
- |
[1] 93 |
| 80 |
Ocaliva |
Obeticholic acid |
D09360 |
[1] NR1H4 |
[1] Bile secretion |
[1] 93 |
| 81 |
Op-724 |
- |
- |
- |
- |
[1] 93 |
| 82 |
Part 1: ljn452 |
- |
- |
- |
- |
[1] 93 |
| 83 |
Part 2: ljn452 dose level 1 |
- |
- |
- |
- |
[1] 93 |
| 84 |
Part 2: ljn452 dose level 2 |
- |
- |
- |
- |
[1] 93 |
| 85 |
Pentoxifylline |
Pentoxifylline |
D00501 |
- |
- |
[10] 26, 56, 84, 93, 96, 113, 220, 222, 296, 298 |
| 86 |
Phenylbutyrate |
Phenylbutyric acid |
D05868 |
- |
- |
[10] 2, 3, 6, 8, 93, 94, 244, 251, 297, 299 |
| 87 |
Pyridoxine |
Pyridoxine |
D02179, D08454 |
- |
- |
[2] 93, 145 |
| 88 |
Pyridoxine 10mg |
Pyridoxine |
D02179, D08454 |
- |
- |
[1] 93 |
| 89 |
Pyridoxine 10mg bp |
Pyridoxine |
D02179, D08454 |
- |
- |
[1] 93 |
| 90 |
Questran |
Cholestyramine |
- |
- |
- |
[3] 93, 254, 297 |
| 91 |
Raltegravir |
Raltegravir |
D06676 |
- |
- |
[4] 13, 26, 93, 265 |
| 92 |
Risedronic acid |
Risedronic acid |
D00942, D03234, D08484 |
[1] FDPS |
[4] Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
[3] 93, 95, 274 |
| 93 |
Rituximab |
Rituximab |
D02994 |
[1] MS4A1 |
[1] Hematopoietic cell lineage |
[42] 11, 13, 14, 17, 35, 36, 43, 44, 45, 46, 49, 50, 51, 52, 53, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 223, 229, 256, 271, 283, 284, 285, 288, 300, 331 |
| 94 |
S-adenosyl-l-methionine |
Methionine |
D00019, D04983 |
- |
- |
[1] 93 |
| 95 |
S-adenosyl-methionine (same) capsules |
Methionine |
D00019, D04983 |
- |
- |
[1] 93 |
| 96 |
Same |
Ademetionine |
D07128 |
- |
- |
[15] 6, 14, 22, 43, 44, 46, 47, 49, 50, 60, 84, 93, 96, 97, 172 |
| 97 |
Saroglitazar |
Saroglitazar |
- |
- |
- |
[1] 93 |
| 98 |
Saroglitazar magnesium 2 mg |
Saroglitazar |
- |
- |
- |
[1] 93 |
| 99 |
Saroglitazar magnesium 4 mg |
Saroglitazar |
- |
- |
- |
[1] 93 |
| 100 |
Seladelpar |
- |
- |
- |
- |
[2] 93, 94 |
| 101 |
Seladelpar 10 mg |
- |
- |
- |
- |
[1] 93 |
| 102 |
Seladelpar 10 mg capsule |
- |
- |
- |
- |
[1] 93 |
| 103 |
Seladelpar 2 mg capsule |
- |
- |
- |
- |
[1] 93 |
| 104 |
Seladelpar 5 mg capsule |
- |
- |
- |
- |
[1] 93 |
| 105 |
Seladelpar 5-10 mg |
- |
- |
- |
- |
[1] 93 |
| 106 |
Sortis |
- |
- |
- |
- |
[1] 93 |
| 107 |
Sortis 10 mg |
- |
- |
- |
- |
[1] 93 |
| 108 |
Sublimated mare milk |
- |
- |
- |
- |
[1] 93 |
| 109 |
Tauroursodeoxycholic acid |
Tauroursodeoxycholic acid |
- |
- |
- |
[4] 2, 13, 93, 299 |
| 110 |
Tauroursodeoxycholic acid capsules |
Tauroursodeoxycholic acid |
- |
- |
- |
[1] 93 |
| 111 |
Tenofovir |
Tenofovir |
D06074 |
- |
- |
[5] 2, 25, 93, 265, 325 |
| 112 |
Tenofovir disoproxil |
Tenofovir disoproxil |
D01982 |
- |
- |
[2] 93, 265 |
| 113 |
Tetrathiomolybdate |
Tetrathiomolybdate |
- |
- |
- |
[3] 85, 93, 171 |
| 114 |
Tigecycline |
Tigecycline |
D01079 |
- |
- |
[1] 93 |
| 115 |
Truvada and kaletra |
- |
- |
- |
- |
[1] 93 |
| 116 |
Udca |
Ursodeoxycholic acid |
D00734 |
[1] NR1H4 |
[1] Bile secretion |
[3] 93, 94, 97 |
| 117 |
Udca (ursodeoxycholic acid) |
Ursodeoxycholic acid |
D00734 |
[1] NR1H4 |
[1] Bile secretion |
[1] 93 |
| 118 |
Udca combined probiotics |
Ursodeoxycholic acid |
D00734 |
[1] NR1H4 |
[1] Bile secretion |
[1] 93 |
| 119 |
Ursodeoxycholic acid |
Ursodeoxycholic acid |
D00734 |
[1] NR1H4 |
[1] Bile secretion |
[8] 6, 67, 84, 93, 94, 95, 96, 97 |
| 120 |
Ursodeoxycholic acid (urso) |
Ursodeoxycholic acid |
D00734 |
[1] NR1H4 |
[1] Bile secretion |
[1] 93 |
| 121 |
Ursodeoxycholic acid 300mg capsule |
Ursodeoxycholic acid |
D00734 |
[1] NR1H4 |
[1] Bile secretion |
[1] 93 |
| 122 |
Ursodeoxycholic acid 300mg tablet |
Ursodeoxycholic acid |
D00734 |
[1] NR1H4 |
[1] Bile secretion |
[1] 93 |
| 123 |
Ursodeoxycholic acid capsules |
Ursodeoxycholic acid |
D00734 |
[1] NR1H4 |
[1] Bile secretion |
[1] 93 |
| 124 |
Ursodeoxycholic acid combination of immunosuppressive agents |
Ursodeoxycholic acid |
D00734 |
[1] NR1H4 |
[1] Bile secretion |
[2] 93, 95 |
| 125 |
Ursodeoxycholsäure |
- |
- |
- |
- |
[1] 93 |
| 126 |
Ursodiol |
Ursodeoxycholic acid |
D00734 |
[1] NR1H4 |
[1] Bile secretion |
[6] 8, 20, 93, 97, 234, 299 |
| 127 |
Ursofalk |
Ursodeoxycholic acid |
D00734 |
[1] NR1H4 |
[1] Bile secretion |
[4] 93, 94, 96, 97 |
| 128 |
Ursofalk® 500 mg film-coated tablets |
- |
- |
- |
- |
[1] 93 |
| 129 |
Ursofalk® 500 mg filmtabletten |
- |
- |
- |
- |
[1] 93 |
| 130 |
Ursofalk® capsules |
- |
- |
- |
- |
[1] 93 |
| 131 |
Ustekinumab |
Ustekinumab |
D09214 |
[3] IL12A, IL12B, IL23A |
[25] African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
[15] 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 |
| 132 |
Ustekinumab 180 mg |
Ustekinumab |
D09214 |
[3] IL12A, IL12B, IL23A |
[25] African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
[1] 93 |
| 133 |
Ustekinumab 45 mg |
Ustekinumab |
D09214 |
[3] IL12A, IL12B, IL23A |
[25] African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
[1] 93 |
| 134 |
Ustekinumab 90 mg |
Ustekinumab |
D09214 |
[3] IL12A, IL12B, IL23A |
[25] African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
[3] 50, 93, 96 |
| 135 |
Vitamin d |
Vitamin d |
- |
- |
- |
[18] 13, 19, 41, 46, 49, 50, 68, 93, 95, 96, 98, 179, 222, 228, 235, 274, 298, 299 |
| 136 |
Zoledronic acid |
Zoledronic acid |
D01968, D06378, D06379, D08689 |
[1] FDPS |
[4] Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
[9] 6, 13, 46, 93, 95, 96, 274, 299, 333 |